LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
A signal peptide (sometimes referred to as signal sequence, targeting signal, localization signal, localization sequence, transit peptide, leader sequence or leader peptide) is a short peptide (usually 16–30 amino acids long) present at the N-terminus (or occasionally nonclassically at the C-terminus or internally) of most newly synthesized proteins that are destined toward the secretory pathway. These proteins include those that reside either inside certain organelles (the endoplasmic reticulum, Golgi or endosomes), secreted from the cell, or inserted into most cellular membranes. Although most type I membrane-bound proteins have signal peptides, most type II and multi-spanning membrane-bound proteins are targeted to the secretory pathway by their first transmembrane domain, which biochemically resembles a signal sequence except that it is not cleaved. They are a kind of target peptide.
== Early life and education == Ramachandran was born on 8 October 1922, in Ernakulam, Kingdom of Cochin, to Tamil parents. He completed his BSc honours in Physics from St Joseph's College, Tiruchirappalli in 1939. He joined the Indian Institute of Science, Bangalore in 1942 in the Electrical Engineering Department. Quickly realising his interest in physics, he switched to the Department of Physics to complete his master's and doctoral thesis under the supervision of Nobel laureate C. V. Raman. In 1942, he received a master's degree in physics from Madras University with his thesis submitted from Bangalore (he did not attend any Madras college at that time). He subsequently received his D.Sc. degree in 1947. Here he mostly studied crystal physics and crystal optics. During his studies he created an X-ray focusing mirror for the X-ray microscope. The resulting field of crystal topography is used in studies involving crystal growth and solid-state reactivity. Ramachandran then spent two years (1947–1949) at the Cavendish Laboratory in Cambridge, where he earned his PhD for 'studies on X-ray diffuse scattering and its application to determination of elastic constants' under the direction of William Alfred Wooster, a leading crystallography expert.
== Signs and symptoms == The various types of VWD present with varying degrees of bleeding tendency, usually in the form of easy bruising, nosebleeds, and bleeding gums. Women may experience heavy menstrual periods and blood loss during childbirth. Symptoms of VWD vary depending on age, sex, and VWD type. In children, bruising and nosebleeds are common symptoms. In adults, easy bruising, heavy menstrual bleeding, and bleeding from minor wounds are more common. Sixty to eighty percent of people with VWD have excessive bleeding after surgery or dental extractions. Gastrointestinal bleeding from dilated blood vessels lining the gut (angiodysplasia) can result in severe, lifethreatening gastrointestinal bleeding. This most commonly occurs in seniors with type 2 or 3 VWD. Von Willebrand factor levels normally increase with age, so disease severity often decreases with older age. In women with VWD, 80% have heavy menstrual bleeding with 20% requiring removal of the uterus (hysterectomy). Due to its association with heavy menstrual bleeding, VWD is more commonly diagnosed in women. Women with VWD may also experience heavy bleeding after delivery (postpartum bleeding). Severe internal bleeding and bleeding into joints are rare in those with VWD, but they are more common in those with the more severe type 3 disease. Bleeding in the brain or spinal cord is exceedingly rare in all 3 types of VWD.
241Pu(16O,xn)257−xNo This reaction was first studied in 1958 at the FLNR. The team measured ~8.8 MeV alpha particles with a half-life of 30 s and assigned to 253,252,251102. A repeat in 1960 produced 8.9 MeV alpha particles with a half-life of 2–40 s and assigned to 253102 from the 4n channel. Confidence in these results was later diminished.
Sources: en.wikipedia.org
== History == On August 10, 1863, the Napa Valley Register first published. It was founded by J.I. Horrell as a pro-Union paper, in contrast to the pro-Succession Napa Echo. By 1864, the newspaper had dropped “Valley” from its name, becoming simply the Napa Register, until returning to the original name over a century later. Editor R.T. Montgomery retired from the paper in January 1866. He returned that May and sold it to N.E. White in January 1868. White left after six months and Montgomery returned again, only to later sell the Register a second time in November 1869 to R.D. Hopkins, formerly editor of the Vallejo Recorder. Hopkins sold to Rev. George W. Henning and George M. Francis in February 1872. The Register moved to daily publication in December 1872. Henning sold out to Charles A. Gardner in May 1873. Gardner left after a few years to run the St. Helena Star. George M. Francis became sole owner of the Register in 1878, upon the death of his business partner. Francis was succeeded in ownership by his son George H. Francis in 1932. The paper remained with Francis and various partners until 1958, when it was sold to Scripps League Newspapers. Scripps was acquired by Pulitzer in 1996, and Pulitzer was acquired by Lee Enterprises in 2005. Dan Evans became the paper's editor in March 2022, and he soon unveiled a newly reconstituted editorial board that October. The board was made up of three members of the newspaper's staff and seven community members. It aimed to assist in driving the official opinion of the paper. In April 2023, the paper laid off two employees.
=== Tg2576 === A useful model for Alzheimer's disease (AD) in the lab is the Tg2576 strain of mice. The K670M and N671L double mutations seen in the human 695 splice-variant of the amyloid precursor protein (APP) are expressed by this strain (also known as the Swedish mutation). A hamster prion protein gene promoter, predominantly in neurons, drives the expression. When compared to non-transgenic littermates, Tg2576 mice show a five-fold rise in Aβ40 and a 10- to 15-fold increase in Aβ42/43. These mice develop senile plaques linked to cellular inflammatory responses because their brains have approximately five times as much transgenic mutant human APP than indigenous mouse APP. The mice exhibit main characteristics of Alzheimer's disease (AD), such as increased generation of amyloid fibrils with aging, plaque formation, and impaired hippocampus learning and memory. Tg2576 mice are a good model for early-stage AD because they show amyloidogenesis and working memory impairments linked to age but do not show neuronal degeneration. The absence of cell death suggests that changes in typical cellular signaling cascades involved in learning and synaptic plasticity are probably linked to the memory phenotype. Associative learning impairments are exacerbated when Tg2576 mice are crossed with PSEN1 transgenic animals that possess the A246E FAD mutation. This crosses promotes the build-up of amyloid and plaque development in the CNS. This lends credence to the theory that AD pathogenesis is influenced by the interplay between APP and PSEN1 gene products.
Line 14: Since 10 September 2016, the Moscow Central Circle (MCC) renovated railroad (the former Moskovskaya Okruzhnaya Zheleznaya Doroga) has been operated as Line 14 of the Moscow Metro. This cone-shaped railroad opened in 1908 (as a freight-only railway from 1934 until the reopening in 2016). Line 11: Another circular metro line—the Big Circle Line (Bolshaya Koltsevaya Liniya)—opened its first stations in 2018 and the remaining stations in 2023. The Kakhovskaya-Savyolovskaya western half of the line was launched in late 2021. The outermost ring within the city is the Moscow Ring Road—often called the MKAD, an acronym for the Russian Московская Кольцевая Автомобильная Дорога—which forms the city's cultural boundary; it was established during the 1950s. It was built at ground level, rather than being elevated, so it forms a barrier to roads that would otherwise pass beneath it. (Before Moscow's 2012 expansion, the MKAD was considered an approximate city boundary.) Outside Moscow, some roads encompassing the city follow the same circular pattern as within city limits; notable examples are the Betonka roads (highways A107 and A108), originally constructed of concrete pads. To reduce traffic on the MKAD, a new ring road—called CKAD, Centralnaya Koltsevaya Avtomobilnaya Doroga, Central Ring Road—was completed outside the MKAD in 2021.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.